Drug intelligence / Profile preview

ABM-1621

Development stage: Unknown
Lead developer: ABM Therapeutics Corporation
Modality: Small Molecules

Overview

ABM-1621 is a small molecule drug candidate developed by ABM Therapeutics Shanghai. It acts as an inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a key regulator in cell death and inflammation pathways. The primary therapeutic focus for this compound is neuroinflammation and related nervous system diseases. As of April 2024, the highest global R&D status for ABM-1621 is at the Discovery stage[1].

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on ABM-1621.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABM-1621.

Explore the full profile